Cellectis (NASDAQ:CLLS) Stock Passes Below 50-Day Moving Average of $1.92

Cellectis S.A. (NASDAQ:CLLS – Get Rating)’s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.92 and traded as low as $1.75. Cellectis shares last traded at $1.78, with a volume of 34,124 shares traded.

Analyst Ratings Changes

Several equities analysts have commented on CLLS shares. Oppenheimer lowered their target price on shares of Cellectis from $16.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, March 13th. Citigroup lowered their price target on Cellectis from $24.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, April 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price target on shares of Cellectis in a research report on Monday, March 13th. StockNews.com initiated coverage on Cellectis in a research report on Thursday, May 18th. They issued a “hold” rating on the stock. Finally, Bryan, Garnier & Co initiated coverage on Cellectis in a research report on Friday, March 17th. They issued a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.25.

Cellectis Trading Up 3.5 %

The company has a debt-to-equity ratio of 0.16, a current ratio of 2.27 and a quick ratio of 2.27. The company’s 50 day moving average is $1.92 and its two-hundred day moving average is $2.25. The firm has a market cap of $98.93 million, a P/E ratio of -0.80 and a beta of 2.12.

Cellectis (NASDAQ:CLLS – Get Rating) last released its earnings results on Wednesday, March 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.18. Cellectis had a negative net margin of 407.96% and a negative return on equity of 70.87%. The business had revenue of $17.32 million during the quarter, compared to analysts’ expectations of $20.48 million. On average, sell-side analysts predict that Cellectis S.A. will post -1.52 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. bought a new position in Cellectis during the third quarter worth about $74,000. Virtu Financial LLC bought a new position in Cellectis during the second quarter worth about $46,000. OLD Mission Capital LLC lifted its stake in Cellectis by 90.0% during the first quarter. OLD Mission Capital LLC now owns 22,329 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 10,577 shares during the period. Balyasny Asset Management LLC bought a new position in Cellectis during the third quarter worth about $42,000. Finally, Two Sigma Investments LP bought a new position in shares of Cellectis in the third quarter valued at approximately $30,000. Institutional investors own 22.61% of the company’s stock.

About Cellectis

(Get Rating)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.